Table 3.

The ratio of IGF-1 and IGFBPs at baseline of study and 8 weeks after the intervention in women with BBT who received BV supplementation (BV group) versus placebo juice consumers

	Baseline (n = 80)				8-weeks follow-up (n = 80)				Absolute treatment effect			Relative treatment effects
Variable	n	Mean	S.D.	Pa	n	Mean	S.D.	Pa	Mean	95% CI	Pc
IGF-1/IGFBP-3d
Control	39	0.6	1.7	N/A	37	0.9	1.8	N/A	N/A	N/A	N/A	1.00
BV	39	0.3	0.4	0.86	40	0.6	1.0	0.18	−0.01	(−0.02–0.1)	0.72	0.99
IGF-1/1GFBP1e
Control	39	90.6	101	N/A	39	38.1	66.1	N/A	N/A	N/A	N/A	1.00
BV	39	90.4	101	0.60	40	40.7	51.0	0.38*	0.90	(−25.8–27.6)	0.95	0.63
IGFBP-3/IGFBP-1f
Control	39	1691.2	1709.6	N/A	37	757.9	1276.7	N/A	N/A	N/A	N/A	1.00
BV	39	1907.5	2429.4	0.70	40	1046.2	1593.1	0.37*	229.1	[(− 336.3)-794.4]	0.42	1.03
IGF-1/(IGFBP-3/IGFBP-1)
Control	36	0.7	1.8	N/A	36	1.0	1.9	N/A	N/A	N/A	N/A	1.00
BV	39	0.4	0.4	0.39	39	0.6	1.1	0.27	−0.3	[(−0.8)-0.1]	0.14	1.16

All data are expressed in geometric mean ± S.D.. N/A: not applied to this model

^aIndependent sample t-test was performed between group

^bPaired t-test was performed to compare within changes in intervention group during the study. ^* Statistical significant difference in within group analysis

^cRepeated measure of ANOVA was carried out in the main effect of model

^dInsulin-like growth factor to insulin-like growth factor binding protein 3 ratio

^eInsulin-like growth factor to insulin-like growth factor binding protein 1 ratio

^fInsulin-like growth factor binding protein 3 to insulin-like growth factor binding protein 1 ratio